DM
Deerfield Management Portfolio holdings
AUM
$5.51B
This Quarter Return
-8.37%
1 Year Return
+12.76%
3 Year Return
+152.98%
5 Year Return
+204.91%
10 Year Return
+993.1%
AUM
$5.26B
AUM Growth
-$1.44B
(-21%)
Cap. Flow
-$1.2B
Cap. Flow
% of AUM
-22.76%
Top 10 Holdings %
Top 10 Hldgs %
53.77%
Holding
466
New
22
Increased
24
Reduced
24
Closed
360
Top Buys
| 1 |
NewAmsterdam Pharma
NAMS
|
$87.7M |
| 2 |
Dynavax Technologies
DVAX
|
$66M |
| 3 |
Oscar Health
OSCR
|
$53.5M |
| 4 |
Legend Biotech
LEGN
|
$50.5M |
| 5 |
Indivior
INDV
|
$47.1M |
Top Sells
| 1 |
Nuvalent
NUVL
|
$157M |
| 2 |
Kura Oncology
KURA
|
$106M |
| 3 |
Catalyst Pharmaceutical
CPRX
|
$64.6M |
| 4 |
Neurocrine Biosciences
NBIX
|
$62.1M |
| 5 |
WAY
Waystar Holding Corp
WAY
|
$60.8M |
Sector Composition
| 1 | Healthcare | 88.36% |
| 2 | Industrials | 0.23% |
| 3 | Consumer Staples | 0.01% |
| 4 | Energy | 0% |
| 5 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
CONMED
CNMD
$1.64B
| $41.9M | 0.79% |
611,964
-2,926
| -0.5% | -$200K |
|
27
Cullinan Oncology
CGEM
$456M
| $41.2M | 0.78% |
3,379,399
+99,399
| +3% | +$1.21M |
|
28
Enhabit
EHAB
$398M
| $39.1M | 0.74% |
5,010,972
+13,226
| +0.3% | +$103K |
|
29
Galapagos
GLPG
$2.06B
| $38.8M | 0.73% |
1,411,000
| – | – |
|
30
Pharvaris
PHVS
$1.41B
| $38.7M | 0.73% |
2,017,464
-14,236
| -0.7% | -$273K |
|
31
Disc Medicine
IRON
$2.14B
| $38.1M | 0.72% |
600,515
-422,750
| -41% | -$26.8M |
|
32
Alnylam Pharmaceuticals
ALNY
$58.6B
| $34.2M | 0.65% |
145,191
+191
| +0.1% | +$44.9K |
|
33
Day One Biopharmaceuticals
DAWN
$766M
| $32.9M | 0.62% |
2,596,033
-21,680
| -0.8% | -$275K |
|
34
Phreesia
PHR
$1.81B
| $32M | 0.61% |
1,271,832
+727,384
| +134% | +$18.3M |
|
|
BCAX
35
Bicara Therapeutics Inc. Common Stock
BCAX
$655M
| $31.3M | 0.59% |
1,795,174
| – | – |
|
36
DocGo
DCGO
$152M
| $30.5M | 0.58% |
7,195,956
-1,870,182
| -21% | -$7.93M |
|
37
InMode
INMD
$917M
| $26.4M | 0.5% |
1,578,708
| – | – |
|
38
Savara
SVRA
$591M
| $24.4M | 0.46% |
7,964,000
+1,498,223
| +23% | +$4.6M |
|
39
CG Oncology
CGON
$2.19B
| $24.4M | 0.46% |
851,593
+898
| +0.1% | +$25.8K |
|
40
Kymera Therapeutics
KYMR
$3.1B
| $23.9M | 0.45% |
+593,000
| New | +$23.9M |
|
|
MREO
41
Mereo BioPharma
MREO
$275M
| $23.5M | 0.44% |
6,710,429
| – | – |
|
42
10x Genomics
TXG
$1.66B
| $21.5M | 0.41% |
1,497,000
-11,943
| -0.8% | -$172K |
|
43
Lantheus
LNTH
$3.75B
| $21.5M | 0.41% |
240,218
| – | – |
|
44
Cogent Biosciences
COGT
$1.83B
| $20.5M | 0.39% |
2,631,000
-1,113,263
| -30% | -$8.68M |
|
|
SEPN
45
Septerna, Inc. Common Stock
SEPN
$628M
| $19.7M | 0.37% |
+861,814
| New | +$19.7M |
|
46
Envista
NVST
$3.37B
| $19.6M | 0.37% |
1,018,415
+998,248
| +4,950% | +$19.3M |
|
47
Vaxcyte
PCVX
$4.17B
| $18.4M | 0.35% |
225,000
| – | – |
|
48
Recursion Pharmaceuticals
RXRX
$2.02B
| $15.6M | 0.3% |
2,315,000
| – | – |
|
49
Foghorn Therapeutics
FHTX
$298M
| $15.4M | 0.29% |
3,255,514
+227,628
| +8% | +$1.07M |
|
50
iRhythm Technologies
IRTC
$5.67B
| $14.1M | 0.27% |
+156,012
| New | +$14.1M |
|